Zofran Report Links Anti-Nausea Drug to Fatal Heart Arrhythmias

Published on March 10, 2015 by Sandy Liebhard

Text-Size:A A A+


A new report warns about cardiovascular issues that may stem from a medication linked to Zofran heart defects, especially when it is taken intravenously, or in high doses.

The report was published this month in the Journal for Nurse Practitioners, and looks at risks of a drug that belongs to a class referred to as selective 5-hydroxytryptamine type 3 (5-HTC) receptor agonists. Among other things, researchers from Mt. Sinai Hospital found that Zofran may result in certain heart rhythm issues depending on how much of the drug was ingested, and whether it was administered intravenously. “Ondansetron has been shown to increase the risk of QT interval prolongation, which can lead to potentially fatal arrhythmias, including torsades de pointes,” according to the report.

The findings of this report were published amid the filing of recent Zofran lawsuits over a drug manufactured by GlaxoSmithKline and approved by the U.S. Food and Drug Administration (FDA) to treat extreme nausea in chemotherapy, radiation and surgery patients. The medication is often prescribed off-label to women during the first trimester of pregnancy, however, which may cause a range of serious problems for their unborn babies. Zofran cleft lips and palates, as well as kidney and heart related issues are among the most serious complications of the medication, as has been suggested by a number of studies.

January Case Study Suggests Zofran Heart Defects

The most recent study involving Zofran heart defects was published during January in Pediatric Emergency Care and looked at two children who died after exposure to the medication. In the first instance, an otherwise healthy 10-year old boy was given Zofran as a treatment for symptoms associated with gastroenteritis, before he developed a faster-than-normal heart rate and died after going unresponsive. An 86-year old baby suffered a similar fate after he too was given Zofran for gastroenteritis.

In 2012, a study found women who were given Zofran during the first pregnancy trimester were 2.37 times more likely to have a child with a separation in the roof of the mouth, also known as a cleft palate. Another bit of research, published in August 2013, found a doubled risk of cardiovascular problems in children who were exposed at that juncture of their fetal development.

Consider a Zofran Lawsuit. Call Us.

Women who had a child with one or more Zofran birth defects may be eligible to file a lawsuit against GlaxoSmithKline. Call our Firm now at .

Web Analytics